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Streptococcus agalactiae (group B Streptococcus [GBS]) is a leading cause of sepsis in neonates. The rate of invasive GBS disease
in nonpregnant adults also continues to climb. Aminoglycosides alone have little or no effect on GBS, but synergistic killing with
penicillin has been shown in vitro. High-level gentamicin resistance (HLGR) in GBS isolates, however, leads to the loss of a syn-
ergistic effect. We therefore performed amulticenter study to determine the frequency of HLGRGBS isolates and to elucidate
the molecular mechanisms leading to gentamicin resistance. From eight centers in four countries, 1,128 invasive and colonizing
GBS isolates were pooled and investigated for the presence of HLGR.We identified two strains that displayed HLGR (BSU1203
and BSU452), both of which carried the aacA-aphD gene, typically conferring HLGR. However, only one strain (BSU1203) also
carried the previously described chromosomal gentamicin resistance transposon designated Tn3706. For the other strain
(BSU452), plasmid purification and subsequent DNA sequencing resulted in the detection of plasmid pIP501 carrying a remnant
of a Tn3 family transposon. Its ability to confer HLGR was proven by transfer into an Enterococcus faecalis isolate. Conversely,
loss of HLGR was documented after curing both GBS BSU452 and the transformed E. faecalis strain from the plasmid. This is
the first report showing plasmid-mediated HLGR in GBS. Thus, in our clinical GBS isolates, HLGR is mediated both chromo-
somally and extrachromosomally.
Streptococcus agalactiae, alternatively designated group B Strep-tococcus (GBS), is a leading cause ofmorbidity andmortality in
neonates andpregnantwomen.Recommendations for diagnosing
maternal GBS colonization and administering intrapartum anti-
microbial prophylaxis have led to a significant decrease in these
infections (1). The rate of invasive GBS disease in nonpregnant
adults, however, continues to climb (2). Elderly persons and those
with underlying diseases—two expanding segments of the popu-
lation—are at increased risk (3). Treatment concepts for invasive
GBS infections in nonpregnant adults have not been established.
Clinical isolates of GBS are susceptible to penicillin, the antimi-
crobial agent of choice for treating invasive diseases. Several pub-
lications advocate the addition of an aminoglycoside to penicillin
or ampicillin for infective endocarditis (4) and periprosthetic
joint infections (5), although aminoglycosides have ototoxic and
nephrotoxic side effects, in particular in the elderly. Aminoglyco-
sides alone have little or no effect on GBS, but synergistic killing
with penicillin has been shown in vitro (6). In case of the presence
of high-level gentamicin resistance (HLGR) in a bacterial isolate,
there is a lack of a synergistic effect.
While HLGR in Enterococcus spp. is frequently found (7), to
the best of our knowledge, only two HLGR GBS strains have been
previously reported (8, 9).Most diagnostic laboratories donot test
routinely for HLGR in GBS. Thus, little is known about the fre-
quency of HLGR GBS, the mechanisms of acquiring HLGR, and
the potential to spread genetic elements associated with HLGR.
The aim of this study was to estimate the frequency of HLGR
GBS isolates (i) in systematically and continuously collected GBS
isolates from colonized pregnant and nonpregnant women and
(ii) in GBS isolates pooled in a collection that stems from various
selected patient populations. Upon detection of HLGR isolates,
we elaborated the molecular mechanism conferring this resis-
tance.
MATERIALS AND METHODS
GBS isolates. The study included 1,128 GBS isolates. Of these, 464 (41%)
were pooled from various GBS collections (Table 1). These isolates stem
from various centers and were previously investigated in other contexts
(10–15). The other 664 (59%) GBS isolates were prospectively collected
and screened for the presence of HLGR. The origin of GBS isolation, the
association with diseases or colonization, and the sampling period are
presented in Table 1.
Definition and identification of HLGR in GBS. No definition of
HLGR in GBS has been published. According to the recommended
screening tests for the detection of HLGR in Enterococcus spp., the resis-
tant isolates have an MIC of500 mg/liter (16). In addition, HLGR iso-
lates with an MIC500 mg/liter have been reported (17, 18). Therefore,
HLGR inGBSwas definedwhen the gentamicinMIC determined by Etest
was 512 mg/liter. All MIC determinations were confirmed with 3
measurements.
Two different methods for the identification of HLGR in GBS were
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applied. Five hundred sixty-one isolates (49.7%) were plated onMueller-
Hinton agar supplemented with 256 mg/liter of gentamicin. Subse-
quently, the MIC of growing GBS colonies was determined by Etest. For
567 (50.3%) isolates, the MIC was primarily determined by Etest without
a prior HLGR screening test.
Bacterial strains. The strains used in this study are presented in Table
2. The plasmid-free recipient used in the mating experiments was Entero-
coccus faecalis (BSU386), a clinical blood culture isolate without HLGR.
Genetic basis of HLGR. Standard recombinant DNA techniques were
used for nucleic acid preparation and analysis. Plasmid DNAwas isolated
and purified using the QIAprep Spin Miniprep kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s instructions. PCR was performed
with Taq polymerase according to the manufacturer’s protocol (Roche
Diagnostics, Mannheim, Germany), with 35 cycles of amplification steps
consisting of 1 min at 94°C, 1 min at 55°C, and 1 min at 72°C. PCR
products were sequenced on an ABI PRISM 310 genetic analyzer, using
the ABI PRISM BigDye Terminator v1.1 cycle sequencing kit (Applied
Biosystems, Weiterstadt, Germany). To identify the HLGR resistance
gene, we performed multiplex PCR as described by Vakulenko et al. (19).
For the detection of Tn3706-specific nucleotide sequences, we used PCR
with primers O1, O2, and O3 as described by Horaud et al. (20). The
primers used for this study are presented in Table 3. Detection of open
TABLE 1 Pooled collection of isolates investigated for the presence of high-level gentamicin resistance
Referencea
No. of GBS
isolatesa Disease/case definition Origin of GBS isolation Study type
Collection
period Geographic origin(s) HLGR
10 75 No disease/colonization Vaginal and rectal swabs
from pregnant and
nonpregnant women
Cross-sectional study 2001–2003 Aachen and Munich,
Germany
0
12 60 EODb with invasive
neonatal GBS infections
Isolation of GBS from
blood or CSFg and
other sterile body
fluids
Part of the prospective
active surveillance
study
2001–2003 Freiburg, Germany 0





Part of the prospective
active surveillance
study
2001–2003 Freiburg, Germany 0
14 30 Patients with cystic
fibrosis
Respiratory samples Collection of isolatesd 2002–2008 Münster, Germany 1
11 150 No disease/colonization Rectovaginal specimens
from pregnant and
nonpregnant women
Part of the national
surveillance study
2005–2009 Lisbon, Portugal 0
97 No disease/colonization Vaginal swabs from
pregnant and
nonpregnant women
—e 2009 Ulm, Germany 0
15 99 No disease/colonization Vaginal swabs from
pregnant and
nonpregnant women
Cross-sectional study 2010 Ismailia, Egypt 0
36 364 No disease/colonization Vaginal swabs from
pregnant women
Cross-sectional study 2009–2010 Bern, Switzerland 1
203 Invasive GBS infections Isolation of GBS from
blood, CSF and other
sterile body fluids
—f 1998–2013 Bern, Switzerland 0
Total 1,128 2
a GBS isolates investigated and published in a context other than the presence of HLGR. The number of GBS isolates investigated for HLGR may vary from the number in the
source publication for technical reasons.
b EOD, early-onset disease.
c For this study, only GBS isolates with serotype III were available.
d GBS isolation occurred during a routine visit or during a visit due to an exacerbation of clinical symptoms.
e Prospective collection during routine diagnostic microbiology laboratory analysis. GBS isolates were investigated for this study.
f Collection of invasive GBS isolates (all age groups) during routine diagnostic microbiology laboratory analysis. GBS isolates were investigated for this study.
g CSF, cerebrospinal fluid.
TABLE 2 Bacterial strains and their corresponding genetic elements conferring HLGR
Species Strain Description MIC of gentamicin (mg/liter) aac(6=)-Ie-aph(2) -Ia gene Transposon
GBS BSU1203 Wild-type strain 1,024 Yes Tn3706
GBS BSU452 Wild-type strain 512 Yes Tn3-like
E. faecalis BSU386 Wild-type strain 12 No No
E. faecalis BSU580 BSU386 pIP501BSU452 1,024 Yes Tn3-like
E. faecalis BSU720 BSU580 cured 12 No No
GBS BSU729 BSU452 cured 24 No No
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reading frames (ORFs) was carried out by using ORF Finder (http://www
.ncbi.nlm.nih.gov/gorf/gorf.html). Sequence comparison was performed
by using the BLAST system (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Transfer andmobilization of the genetic element conferringHLGR.
To investigate the potential transfer of resistance, we transformedE. faeca-
lis (BSU386) with plasmid DNA, as described previously (21). Curing the
transformed E. faecalis strain and GBS BSU452 with HLGR was achieved
as follows. The strainswere exposed in an overnight culture to serial 2-fold
dilutions of ciprofloxacin in Todd-Hewitt broth plus 0.5% yeast extract
and Luria-Bertani medium. Bacterial cultures containing the highest sub-
inhibitory concentrations of ciprofloxacin (i.e., 0.625 mg/liter for GBS
BSU452 and 10mg/liter for E. faecalis BSU580) were plated on antibiotic-
free tryptic soy agar blood plates and grown overnight at 37°C. Single
colonieswere then tested for loss of resistance to gentamicin by subculture
onto Mueller-Hinton agar plates containing 256 mg/liter of gentamicin.
The MIC for gentamicin was then determined by Etest.
Nucleotide sequence accession number. Nucleotide sequences were
submitted to GenBank under accession number KP698941.
RESULTS
GBS isolates withHLGR.Among 1,128 GBS isolates, 2 (0.17%)
strains with HLGR were identified. One strain (BSU1203;
MIC, 1,024 mg/liter) was obtained from a 35-year-old Swiss
woman during prenatal screening. The second HLGR GBS
strain (BSU452; MIC, 512 mg/liter) was isolated in a respira-
tory specimen from a 26-year-old man with cystic fibrosis.
PCR detection of genes conferring HLGR on GBS. To inves-
tigate the resistance determinants in HLGR GBS strains, we per-
formed PCRs that were specific for the aac(6=)-Ie-aph(2)-Ia gene
and the flanking IS256 element (19). The aac(6=)-Ie-aph(2)-Ia
gene was readily detected in both strains, yielding the expected
product of 348 bp (19).
Detection of a previously known transposon and a novel el-
ement. A PCR with a primer set annealing on the structural gen-
tamicin resistance gene and the IS256 sequence, located down-
streamof this gene, showed the expected 369-bpproduct for strain
GBS BSU1203 (19), indicating the presence of the previously de-
scribed chromosomal transposon Tn3706. For further character-
ization of the resistance determinant, PCRs that were specific for
insertion sequence elements of Tn3706 were performed as pub-
lished previously (20). These PCRs were positive with GBS strain
BSU1203 andmatched those previously described for HLGRGBS
strain B128 (20), confirming the presence of Tn3706. In GBS
strain BSU452, the aac(6=)-Ie-aph(2)-Ia gene was found, but
none of the PCRs specific for the transposon structures of Tn5281,
Tn4001, or Tn3706 (20) yielded a product, suggesting the presence
of a novel HLGR determinant in this strain.
Characterization of a novel mobile genetic element confer-
ring HLGR on GBS. To identify the genetic structure of GBS
strain BSU452 carrying the aac(6=)-Ie-aph(2)-Ia gene, we per-
formed an inverse PCR on a plasmid preparation of BSU452.
Primers annealing to the gentamicin resistance gene (Table 3) and
directed toward DNA regions upstream and downstream of
aac(6=)-Ie-aph(2)-Ia yielded a PCR product about 2 kb in length,
which was completely sequenced. Nucleotide comparison with
theGenBank database revealed a 100% identity of nucleotides 1 to
253 and 721 to 2029 with plasmid pTEF1 of E. faecalis strain V583
(GenBank accession number AE016833.1). Several ORFs were
identified on the 2-kb PCR product, and comparison of the de-
duced amino acids with the GenBank database revealed a DNA
resolvase fragment and one copy of an insertion sequence element
with high homology to IS1216. This structure displayed high sim-
ilarities to a Tn3 family transposon.
Transfer and mobilization of the resistance determinant in
association with HLGR. The HLGR genes and the flanking DNA
sequences inGBSBSU1203matched those previously identified in
GBS B128, and because thorough molecular analyses on the ac-
quisition of HLGR have been published for that strain (8, 20, 22),
further investigations focused on GBS BSU452. Tn3 family trans-
posons are typically located on plasmids. To investigate if this is
the case in strain GBS BSU452 and to characterize the potential of
spreading HLGR to other isolates, we transformed the gentami-
cin-susceptible E. faecalis strain BSU386 with the plasmid prepa-
ration obtained from GBS BSU452. Positive clones (i.e., desig-
nated E. faecalis BSU580, which carries the mobile element of
BSU452) were obtained upon plating the transformed strain onto
the HLGR screening agar, as described above. A subsequent gen-
tamicin evaluation revealed an increase in MIC from 12 mg/liter
to1,024mg/liter (Table 2). To ensure that the increasedMICwas
due to the uptake of the plasmid DNA, plasmid preparations were
subjected togel electrophoresis (Fig.1),whichshowedthepresenceof
large plasmids in the HLGR strains BSU452 and BSU580. Further
confirmationof the successful transferwas achievedbyPCR showing
thepresenceof theaac(6=)-Ie-aph(2)-Ia gene anda lackof anyflank-
ing IS256 sequences in E. faecalis strain BSU580. To confirm that
the newly detected mobile genetic element is indeed located on a
plasmid, we attempted to cure GBS BSU452 and the transformed
E. faecalis BSU580 from the plasmid. This was successfully
achieved by growing the strains in subinhibitory conditions of
ciprofloxacin, as described by Eliopoulos et al. (23). Under these
conditions, clones of both GBS BSU452 and the transformed E.
faecalis strain BSU580 lost their elevated resistance to gentamicin.
The MICs decreased in GBS strain BSU729 (i.e., strain BSU452
after plasmid curing) from 512 mg/liter to 24 mg/liter and in
E. faecalis BSU720 (i.e., strain BSU580 after plasmid curing)
from 1,024 mg/liter to 12 mg/liter (Table 2). In addition, the
lack of a plasmid in the cured strains could be demonstrated by gel
electrophoresis (Fig. 1). Plasmid loss in the presence of subinhibi-
tory ciprofloxacin occurred at a frequency of about 0.02% (1 in
4,500 colonies inGBS and 1 in 6,000 colonies ofE. faecalis). One of
the most commonly found plasmids in GBS and enterococci is
TABLE 3 Primers used for PCR and DNA sequencing
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pIP501. To determine if the detected plasmid is pIP501, the plas-
mid preparation obtained from GBS BSU 452 was subjected to
PCR as detailed elsewhere (24). PCR products were sequenced
and the presence of pIP501 in GBS BSU452 was confirmed.
DISCUSSION
In contrast to screens for Enterococcus spp., GBS surveillance
schemes usually do not include gentamicin susceptibility testing,
and screening for HLGR is often omitted in clinical laboratories.
The prevalence of HLGR in GBS is, therefore, unknown. Previ-
ously, two HLGR GBS strains were reported. One of them (B128)
was isolated from an infected leg wound in 1987 (8) and the other
from a 49-year-old woman with a urinary tract infection, as pub-
lished in 2002 (9). We identified two further colonizing strains in
a collection of more than 1,000 isolates (0.17%). This proportion
is in contrast to that in a previously published Argentinian study
(18). Among 141 strains, the authors found 13.5% HLGR GBS.
Although no firm epidemiological conclusion about the fre-
quency of HLGR isolates can be made on the basis of these two
studies, it should be noted that up to 20% to 35% of women are
colonized with GBS (25) and that the absolute number of HLGR
GBS isolates may be much higher than previously estimated (26).
Thus, for a patient receiving penicillin-gentamicin combination
therapy for invasive GBS infection, and considering the potential
side effects of aminoglycosides, the presence of HLGR is of signif-
icant clinical relevance.
Investigations on the genetic basis forHLGR inE. faecalis led to
the identification of the aacA-aphD gene (27). It is typically found
on the composite transposon Tn5281. The transposon resembles
Tn4001 in Staphylococcus aureus and is characterized by the pres-
ence of two IS256 copies flanking the transposon structure. The
aacA-aphD gene, later designated aac(6=)-aph(2), encodes a bi-
functional enzyme with an acetyltransferase and a phosphotrans-
ferase function. The enzyme catalyzes inactivation of the vast ma-
jority of aminoglycosides, with the exception of streptomycin. In
most Enterococcus spp. with HLGR, the transposon harboring the
aac(6=)-aph(2) gene is found on a plasmid (28). Truncated forms
of Tn4001 are typically located on plasmid DNA (29). Intact
Tn4001 transposons can also be located on chromosomalDNA. In
the previously described HLGR GBS strain B128, the aacA-aphD
gene was found on a Tn4001 derivative (designated Tn3706), lo-
cated on chromosomalDNA (8). In one of our strains (BSU1203),
the finding of transposon Tn3706 conferring HLGR is in agree-
ment with the previously published findings about HLGR GBS
strain B128 (8, 20, 22). Horaud et al. (20) described that its trans-
position from E. faecalis occurred on GBS plasmid pIP501. How-
ever, after conjugative transfer between GBS strains, the hybrid
replicons pIP501::Tn3706 were found to be structurally unstable.
This observation indicated that streptococcal pIP501-like plas-
mids do not constitute appropriate delivery vectors for the dis-
semination of Tn3706 among GBS, and therefore, HLGR is found
relatively rarely among GBS isolates (20). Although these argu-
ments speak against a high potential for spread, the persistence of
HLGR inGBS strain B128 andBSU1203 indicates that Tn3706 can
be stably integrated into the chromosome.
In GBS BSU452, we identified a different mobile genetic ele-
ment. The genes surrounding the aac(6=)-aph(2) gene did not
display the structures of transposonTn4001or of any of the closely
related derivatives or its truncated forms. We detected plasmid
pIP501, which is a conjugative plasmid that often carries multire-
sistance genes. It has previously been described for S. agalactiae in
association with HLGR and belongs to the Inc18 group of plas-
mids (24). Tn3 family transposons are commonly associated with
Inc18 plasmids and often confer antibiotic resistance on Entero-
coccus spp. (30). They are, however, typically associated with gly-
copeptide and macrolide resistance (31) and not HLGR. Investi-
gators have previously reported the presence of an IS1216
transposase on Tn3-like remnants (32), as we found in our GBS
BSU452 strain; however, IS1216 is typically associated with tetra-
cycline resistance in streptococcal species (33). To the best of our
knowledge, the detection of the aacA-aphD gene on a Tn3-like
transposon and the presence of IS216 in association with HLGR
constitute novel findings. They have been reported neither for
enterococci nor for GBS.
The resistance determinant in GBS BSU452 shows close ho-
mologies to parts of the enterococcal resistance plasmid pTEF1 of
E. faecalis strain V583 (34), suggesting that it may have been
transferred through horizontal gene transfer. This is, however,
speculative for GBS strain BSU452, since the presence of an
HLGR Tn3-like transposon in GBS has not been previously
described. Nevertheless, horizontal gene transfer of resistance
genes from Enterococcus spp. to other Gram-positive bacteria by
mobile genetic elements is a well-described mechanism in the
spread of antibiotic resistance (30, 31). Horizontal gene transfer
has recently been suggested for the acquisition of vancomycin
resistance genes in GBS (35). GBS strain BSU452 was isolated from
the sputum of a cystic fibrosis patient, but there was no evidence of
enterococcal colonization. Considering that patients with cystic fi-
brosis are often treatedwith antibiotics (including aminoglycosides),
and theirmicrobiome in the respiratory tract is different from that of
untreated healthy patients, it is possible that horizontal gene transfer
to GBS originated from the selected flora. However, this hypoth-
esis cannot be proven in our case and remains speculation.
Though a plasmid-borne HLGR has high potential for further
spread in a GBS population, the likelihood of this happening can-
FIG 1 Plasmid preparations of GBS and E. faecalis strains. Shown are plasmid
preparations of E. faecalis andGBS strains separated by agarose gel electropho-
resis (0.8% gel). Lanes: 1, E. faecalis strain BSU386 (wild-type strain without
HLGR); 2, E. faecalis strain BSU580 (wild-type strain BSU386 after transfor-
mation with plasmid preparation from S. agalactiae strain BSU452, displaying
HLGR); 3, E. faecalis strain BSU720 (E. faecalis strain BSU580 after plasmid
curing and loss of HLGR); 4, S. agalactiae strain BSU452 (patient isolate dis-
playing HLGR); 5, S. agalactiae strain BSU729 (S. agalactiae strain BSU452
after plasmid curing and loss of HLGR). M, molecular size marker.
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not be predicted yet. In this study, we demonstrated that pIP501,
including the HLGR determinant of GBS452, could easily be
transferred to E. faecalis. Thus, it is conceivable that transfer to
otherGBS isolates is also possible, especially in view of the fact that
pIP501 is a broad-host-range plasmid, well established inGBS and
enterococci.
In conclusion, the overall frequency of HLGR GBS in our
large collection of isolates was low. Molecular investigations
revealed a transposon located on the chromosome, as previ-
ously described for a single isolate (8, 20, 22), and a Tn3 family
transposon conferring HLGR in association with pIP501.
These findings point toward a new dimension of potential
spread of HLGR within GBS.
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